2-[1-(tert-Butoxycarbonyl)-piperidin-4-yl]-3H-quinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[1-(tert-Butoxycarbonyl)-piperidin-4-yl]-3H-quinazolin-4-one
• 英文别名: tert-butyl 4-(4-oxo-3H-quinazolin-2-yl)piperidine-1-carboxylate
• 化学式: C₁₈H₂₃N₃O₃
• 分子量: 329.399
• InChiKey: JGOLJGZEQLHEKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[1-(tert-Butoxycarbonyl)-piperidin-4-yl]-3H-quinazolin-4-one 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以66 %的产率得到2-(piperidin-4-yl)quinazolin-4(3H)-one
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUND
  [FR] COMPOSÉ PHARMACEUTIQUE

  摘要：

  A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; R1 and R2 may together form a ring; R3 is independently selected from H and a substituted or unsubstituted organic group; R6 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; Z1 and Z2 are independently selected from C and N; and L comprises an organic group as defined herein.

  公开号：

  WO2023156386A2
• 作为产物：
  描述：

  tert-butyl 4-((2-carbamoylphenyl)carbamoyl)piperidine-1-carboxylate 在 potassium hydroxide 作用下， 以 二乙二醇二甲醚 为溶剂， 以97 %的产率得到2-[1-(tert-Butoxycarbonyl)-piperidin-4-yl]-3H-quinazolin-4-one
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUND
  [FR] COMPOSÉ PHARMACEUTIQUE

  摘要：

  A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; R1 and R2 may together form a ring; R3 is independently selected from H and a substituted or unsubstituted organic group; R6 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; Z1 and Z2 are independently selected from C and N; and L comprises an organic group as defined herein.

  公开号：

  WO2023156386A2

文献信息

• Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones
  申请人：——

  公开号：US20010051627A1

  公开（公告）日：2001-12-13

  This invention relates to compounds which are generally alpha 1A/B -receptor antagonists and which are represented by Formula I: 1 wherein the substituents are as defined in the specification; or pharmaceutically acceptable salts, hydrates, or N-oxides thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and a process for their preparation.

  本发明涉及的化合物一般为 alpha 1A/B -受体拮抗剂，由式 I 表示： 1 其中取代基如说明书中所定义；或其药学上可接受的盐、水合物或 N-氧化物。本发明还涉及含有此类化合物的药物组合物、将其用作治疗剂的方法及其制备工艺。
• US6258819B1
  申请人：——

  公开号：US6258819B1

  公开（公告）日：2001-07-10
• US6376500B2
  申请人：——

  公开号：US6376500B2

  公开（公告）日：2002-04-23
• [EN] PHARMACEUTICAL COMPOUND<br/>[FR] COMPOSÉ PHARMACEUTIQUE
  申请人：[en]DUKE STREET BIO LIMITED

  公开号：WO2023156386A2

  公开（公告）日：2023-08-24

  A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; R1 and R2 may together form a ring; R3 is independently selected from H and a substituted or unsubstituted organic group; R6 may be present or absent and is independently selected from H and a substituted or unsubstituted organic group; Z1 and Z2 are independently selected from C and N; and L comprises an organic group as defined herein.